Search Results

There are 2991867 results for: content related to: Novel targeted therapies in inflammatory breast cancer

  1. You have free access to this content
    Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo

    International Journal of Cancer

    Volume 126, Issue 12, 15 June 2010, Pages: 2893–2903, Michael A. Morse, Junping Wei, Zachary Hartman, Wenle Xia, Xiu-Rong Ren, Gangjun Lei, William T. Barry, Takuya Osada, Amy C. Hobeika, Sharon Peplinski, Haixiang Jiang, Gayathri R. Devi, Wei Chen, Neil Spector, Andrea Amalfitano, H. Kim Lyerly and Timothy M. Clay

    Article first published online : 23 OCT 2009, DOI: 10.1002/ijc.24995

  2. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants

    Fundamental & Clinical Pharmacology

    Volume 26, Issue 4, August 2012, Pages: 530–537, Mohamed Chefrour, Gérard Milano, Patricia Formento, Sarah Giacometti, Amine Denden, Nicole Renée, Athanassios Iliadis, Jean-Louis Fischel and Joseph Ciccolini

    Article first published online : 30 MAY 2011, DOI: 10.1111/j.1472-8206.2011.00945.x

  3. Quercetin-3-methyl ether inhibits lapatinib-sensitive and -resistant breast cancer cell growth by inducing G2/M arrest and apoptosis

    Molecular Carcinogenesis

    Volume 52, Issue 2, February 2013, Pages: 134–143, Jixia Li, Feng Zhu, Ronald A. Lubet, Antonella De Luca, Clinton Grubbs, Marna E. Ericson, Amelia D'Alessio, Nicola Normanno, Zigang Dong and Ann M. Bode

    Article first published online : 15 NOV 2011, DOI: 10.1002/mc.21839

  4. You have full text access to this Open Access content
    Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells

    Cancer Science

    Volume 101, Issue 10, October 2010, Pages: 2220–2226, Chuandong Ma, Xiuqing Niu, Jianmin Luo, Zhimin Shao and Kunwei Shen

    Article first published online : 1 JUL 2010, DOI: 10.1111/j.1349-7006.2010.01662.x

  5. You have free access to this content
    The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38

    International Journal of Cancer

    Volume 125, Issue 12, 15 December 2009, Pages: 2957–2969, Melissa J. LaBonte, Philipp C. Manegold, Peter M. Wilson, Will Fazzone, Stan G. Louie, Heinz-Josef Lenz and Robert D. Ladner

    Article first published online : 17 JUN 2009, DOI: 10.1002/ijc.24658

  6. Addition of amino acid moieties to lapatinib increases the anti-cancer effect via amino acid transporters

    Biopharmaceutics & Drug Disposition

    Volume 35, Issue 1, January 2014, Pages: 60–69, Han-Joo Maeng, Eun-Seo Kim, Chieyeon Chough, Misuk Joung, Jee Woong Lim, Chang-Koo Shim and Won-Sik Shim

    Article first published online : 19 NOV 2013, DOI: 10.1002/bdd.1872

  7. You have free access to this content
    Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors

    Cytometry Part A

    Volume 79A, Issue 9, September 2011, Pages: 684–693, Simone Diermeier-Daucher, Stefanie Breindl, Stefan Buchholz, Olaf Ortmann and Gero Brockhoff

    Article first published online : 22 JUL 2011, DOI: 10.1002/cyto.a.21107

  8. Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma

    Diseases of the Esophagus

    Volume 26, Issue 5, July 2013, Pages: 487–495, X. F. Guo, X. F. Zhu, G. S. Zhong and B. G. Deng

    Article first published online : 27 MAR 2012, DOI: 10.1111/j.1442-2050.2012.01332.x

  9. You have free access to this content
    Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines

    International Journal of Cancer

    Volume 129, Issue 10, 15 November 2011, Pages: 2408–2416, Kousaku Mimura, Koji Kono, Takanori Maruyama, Mitsuaki Watanabe, Shinichiro Izawa, Shugo Shiba, Yoshiki Mizukami, Yoshihiko Kawaguchi, Masayuki Inoue, Tetsuo Kono, Aniruddha Choudhury, Rolf Kiessling and Hideki Fujii

    Article first published online : 8 APR 2011, DOI: 10.1002/ijc.25896

  10. You have free access to this content
    Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy


    Volume 52, Issue 3, September 2010, Pages: 975–986, Zichen Zhang, Regina A. Oyesanya, Deanna J. W. Campbell, Jorge A. Almenara, Jennifer L. DeWitt and Alphonse E. Sirica

    Article first published online : 20 MAY 2010, DOI: 10.1002/hep.23773

  11. Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth

    Journal of Cellular Physiology

    Volume 226, Issue 1, January 2011, Pages: 52–57, Alejandro Vazquez-Martin, Cristina Oliveras-Ferraros, Silvia Cufí, Sonia Del Barco, Begoña Martin-Castillo and Javier A. Menendez

    Article first published online : 23 JUL 2010, DOI: 10.1002/jcp.22333

  12. Lapatinib and Ixabepilone for the Treatment of Metastatic Breast Cancer

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 28, Issue 10, October 2008, Pages: 1255–1266, Patti A. Halterman

    Article first published online : 6 JAN 2012, DOI: 10.1592/phco.28.10.1255

  13. You have free access to this content
    Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2-positive breast cancer

    Asia-Pacific Journal of Clinical Oncology

    Volume 5, Issue 1, March 2009, Pages: 4–16, Raymond D SNYDER, Frances M BOYLE, Arlene CHAN, Paul S CRAFT, Richard DE BOER, Paul N MAINWARING, Nicole J McCARTHY and Nicholas R WILCKEN

    Article first published online : 24 FEB 2009, DOI: 10.1111/j.1743-7563.2009.01194.x

  14. You have full text access to this Open Access content
    In vitro and in vivo evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer

    Cancer Science

    Volume 101, Issue 2, February 2010, Pages: 468–473, Masahiro Komoto, Bunzo Nakata, Takafumi Nishii, Hidemi Kawajiri, Osamu Shinto, Ryosuke Amano, Nobuya Yamada, Masakazu Yashiro and Kosei Hirakawa

    Article first published online : 16 OCT 2009, DOI: 10.1111/j.1349-7006.2009.01405.x

  15. You have full text access to this OnlineOpen article
    Activated estrogen receptor-mitogen-activated protein kinases cross talk confer acquired resistance to lapatinib

    Thoracic Cancer

    Zhe Li, Sheng-Sheng Yang, Pei-Hao Yin, Tao Chang, Lin-Xiang Shi, Lin Fang and Guo-En Fang

    Article first published online : 13 FEB 2015, DOI: 10.1111/1759-7714.12239

  16. You have free access to this content
    Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb®, GW572016) in an expanded panel of human normal and tumour cell lines

    Cell Proliferation

    Volume 40, Issue 4, August 2007, Pages: 580–594, D. W. Rusnak, K. J. Alligood, R. J. Mullin, G. M. Spehar, C. Arenas-Elliott, A.-M. Martin, Y. Degenhardt, S. K. Rudolph, T. F. Jr Haws, B. L. Hudson-Curtis and T. M. Gilmer

    Article first published online : 16 JUL 2007, DOI: 10.1111/j.1365-2184.2007.00455.x

  17. You have free access to this content
    Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy


    Volume 117, Issue 21, 1 November 2011, Pages: 5013–5020, Allan Lipton, Kim Leitzel, Suhail M. Ali, Walter Carney, Greg Platek, Klaudia Steplewski, Ron Westlund, Robert Gagnon, Anne-Marie Martin and Julie Maltzman

    Article first published online : 31 MAR 2011, DOI: 10.1002/cncr.26101

  18. Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program

    Pediatric Blood & Cancer

    Volume 53, Issue 4, October 2009, Pages: 594–598, Richard Gorlick, E. Anders Kolb, Peter J. Houghton, Christopher L. Morton, Doris Phelps, Paula Schaiquevich, Clinton Stewart, Stephen T. Keir, Richard Lock, Hernan Carol, C. Patrick Reynolds, John M. Maris, Jianrong Wu and Malcolm A. Smith

    Article first published online : 24 JUN 2009, DOI: 10.1002/pbc.21989

  19. Sustained Zero-Order Release of Intact Ultra-Stable Drug-Loaded Liposomes from an Implantable Nanochannel Delivery System

    Advanced Healthcare Materials

    Volume 3, Issue 2, February, 2014, Pages: 230–238, Christian Celia, Silvia Ferrati, Shyam Bansal, Anne L. van de Ven, Barbara Ruozi, Erika Zabre, Sharath Hosali, Donatella Paolino, Maria Grazia Sarpietro, Daniel Fine, Massimo Fresta, Mauro Ferrari and Alessandro Grattoni

    Article first published online : 23 JUL 2013, DOI: 10.1002/adhm.201300188

  20. Therapeutic efficiency of everolimus and lapatinib in xenograft model of human colorectal carcinoma with KRAS mutation

    Fundamental & Clinical Pharmacology

    Volume 27, Issue 4, August 2013, Pages: 434–442, Céline Chu, Marie-Sophie Noël-Hudson, Valérie Boige, Diane Goéré, Sylvie Marion, Mélanie Polrot, Ludovic Bigot, Patrick Gonin, Robert Farinotti and Laurence Bonhomme-Faivre

    Article first published online : 28 MAR 2012, DOI: 10.1111/j.1472-8206.2012.01035.x